139 related articles for article (PubMed ID: 15853762)
1. Accelerated cytotoxicity mechanism screening using drug metabolising enzyme modulators.
O'Brien PJ; Siraki AG
Curr Drug Metab; 2005 Apr; 6(2):101-9. PubMed ID: 15853762
[TBL] [Abstract][Full Text] [Related]
2. Human and animal hepatocytes in vitro with extrapolation in vivo.
O'Brien PJ; Chan K; Silber PM
Chem Biol Interact; 2004 Nov; 150(1):97-114. PubMed ID: 15522264
[TBL] [Abstract][Full Text] [Related]
3. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development.
Baranczewski P; Stańczak A; Sundberg K; Svensson R; Wallin A; Jansson J; Garberg P; Postlind H
Pharmacol Rep; 2006; 58(4):453-72. PubMed ID: 16963792
[TBL] [Abstract][Full Text] [Related]
4. An update on metabolism studies using human hepatocytes in primary culture.
Gómez-Lechón MJ; Castell JV; Donato MT
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):837-54. PubMed ID: 18624674
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of potential hepatotoxicity induced by drugs.
Gómez-Lechón MJ; Lahoz A; Gombau L; Castell JV; Donato MT
Curr Pharm Des; 2010 Jun; 16(17):1963-77. PubMed ID: 20236064
[TBL] [Abstract][Full Text] [Related]
6. New technologies and screening strategies for hepatotoxicity: use of in vitro models.
Dambach DM; Andrews BA; Moulin F
Toxicol Pathol; 2005; 33(1):17-26. PubMed ID: 15805052
[TBL] [Abstract][Full Text] [Related]
7. Metabolic mechanisms of methanol/formaldehyde in isolated rat hepatocytes: carbonyl-metabolizing enzymes versus oxidative stress.
MacAllister SL; Choi J; Dedina L; O'Brien PJ
Chem Biol Interact; 2011 May; 191(1-3):308-14. PubMed ID: 21276436
[TBL] [Abstract][Full Text] [Related]
8. The application of HepRG cells in evaluation of cytochrome P450 induction properties of drug compounds.
Andersson TB
Methods Mol Biol; 2010; 640():375-87. PubMed ID: 20645063
[TBL] [Abstract][Full Text] [Related]
9. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.
Luo G; Cunningham M; Kim S; Burn T; Lin J; Sinz M; Hamilton G; Rizzo C; Jolley S; Gilbert D; Downey A; Mudra D; Graham R; Carroll K; Xie J; Madan A; Parkinson A; Christ D; Selling B; LeCluyse E; Gan LS
Drug Metab Dispos; 2002 Jul; 30(7):795-804. PubMed ID: 12065438
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes.
Prueksaritanont T; Richards KM; Qiu Y; Strong-Basalyga K; Miller A; Li C; Eisenhandler R; Carlini EJ
Pharm Res; 2005 Jan; 22(1):71-8. PubMed ID: 15771232
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
Utkarsh D; Loretz C; Li AP
Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
[TBL] [Abstract][Full Text] [Related]
12. The use of human hepatocytes to investigate drug metabolism and CYP enzyme induction.
Klieber S; Torreilles F; Guillou F; Fabre G
Methods Mol Biol; 2010; 640():295-308. PubMed ID: 20645059
[TBL] [Abstract][Full Text] [Related]
13. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
Yan Z; Caldwell GW
Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
[TBL] [Abstract][Full Text] [Related]
14. Utility of mass spectrometry for in-vitro ADME assays.
Chu I; Nomeir AA
Curr Drug Metab; 2006 Jun; 7(5):467-77. PubMed ID: 16787156
[TBL] [Abstract][Full Text] [Related]
15. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential.
Li AP; Lu C; Brent JA; Pham C; Fackett A; Ruegg CE; Silber PM
Chem Biol Interact; 1999 Jun; 121(1):17-35. PubMed ID: 10418968
[TBL] [Abstract][Full Text] [Related]
16. Molecular cytotoxic mechanisms of chlorpromazine in isolated rat hepatocytes.
MacAllister SL; Young C; Guzdek A; Zhidkov N; O'Brien PJ
Can J Physiol Pharmacol; 2013 Jan; 91(1):56-63. PubMed ID: 23368734
[TBL] [Abstract][Full Text] [Related]
17. Human hepatocytes as a tool for studying toxicity and drug metabolism.
Gómez-Lechón MJ; Donato MT; Castell JV; Jover R
Curr Drug Metab; 2003 Aug; 4(4):292-312. PubMed ID: 12871046
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles.
Zhang J; Doshi U; Suzuki A; Chang CW; Borlak J; Li AP; Tong W
Chem Biol Interact; 2016 Aug; 255():3-11. PubMed ID: 26581450
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures.
Yokoyama Y; Sasaki Y; Terasaki N; Kawataki T; Takekawa K; Iwase Y; Shimizu T; Sanoh S; Ohta S
Biol Pharm Bull; 2018 May; 41(5):722-732. PubMed ID: 29445054
[TBL] [Abstract][Full Text] [Related]
20. In vitro assessment of P450 induction potential of novel chemopreventive agents SR13668, 9-cis-UAB30, and pentamethychromanol in primary cultures of human hepatocytes.
Jackson JP; Kabirov KK; Kapetanovic IM; Lyubimov A
Chem Biol Interact; 2009 May; 179(2-3):263-72. PubMed ID: 19135037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
